Why the study?
Does von Willebrand factor/factor VIII concentrate provide effective haemostasis and safety in patients with von Willebrand disease undergoing elective surgery?
Does von Willebrand factor/factor VIII concentrate provide effective haemostasis and safety in patients with von Willebrand disease undergoing elective surgery?
VWF/FVIII concentrate is safe and effective for preventing excessive bleeding during and after elective surgery in patients with von Willebrand disease.
Answers are grounded in this paper and cite their sources.
May support perioperative haemostasis with VWF/FVIII concentrate in von Willebrand disease; extends pharmacokinetic data but leaves open randomized confirmation.
von Willebrand disease (VWD) is the most common inherited bleeding disorder. Treatment guidelines recommend the use of von Willebrand factor/factor VIII (VWF/FVIII) concentrate for VWD patients with type 2 or 3 VWD undergoing surgery, and type 1 patients undergoing surgery who are unresponsive, or for whom desmopressin acetate is contraindicated. This prospective, open-label, multinational study evaluated the safety, efficacy and optimal dosing of a VWF/FVIII concentrate (Humate-P) in subjects with VWD undergoing elective surgery. Dosing was based on VWF ristocetin cofactor (VWF:RCo) and FVIII pharmacokinetic assessments performed before surgery. Pharmacokinetic assessments were completed in 33 adults and 9 children. Haemostatic efficacy was assessed on a 4-point scale (excellent, good, moderate/poor or none). Overall effective haemostasis was achieved in 32/35 subjects. Median terminal VWF:RCo half-life was 11.7 h, and median incremental in vivo recovery was 2.4 IU dL(-1) per IU kg(-1) infused. Major haemorrhage occurred after surgery in 3/35 cases despite achieving target VWF and FVIII levels. Median VWF/FVIII concentrate loading doses ranged from 42.6 IU VWF:RCo kg(-1) (oral surgery) to 61.2 IU VWF:RCo kg(-1) (major surgery), with a median of 10 (range, 2-55) doses administered per subject. Adverse events considered possibly treatment-related (n = 6) were generally mild and of short duration. The results indicate that this VWF/FVIII concentrate is safe and effective in the prevention of excessive bleeding during and after surgery in individuals with VWD.
No takes yet. Share an insight, caveat, or question.
Gill et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: